



**University of
Zurich**^{UZH}

**Zurich Open Repository and
Archive**

University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch

Year: 2014

Trends in hepatic cancer survival in Switzerland

Dufour, Jean-François ; Bordoni, Andrea ; Lorez, Matthias

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-107944>

Journal Article

Originally published at:

Dufour, Jean-François; Bordoni, Andrea; Lorez, Matthias (2014). Trends in hepatic cancer survival in Switzerland. Schweizer Krebsbulletin, 34(1):46-50.

Trends in Hepatic Cancer Survival in Switzerland

Jean-Francois Dufour^{1,2}, Andrea Bordoni³, Matthias Lorez⁴ and the NICER Working Group^s

¹ University Clinic for Visceral Surgery and Medicine, Inselspital, Bern

² Hepatology, Department of Clinical Research, University of Bern, Bern

³ Registro tumori del Ticino, Istituto cantonale di patologia, Locarno

⁴ National Institute for Cancer Epidemiology and Registration (NICER), c/o University of Zurich

Keywords: hepatic cancer, observed survival, relative survival, survival, Switzerland

Introduction

Swiss incidence as well as mortality rates for liver cancer have increased only slightly over the last 20 years [1]. The ratio of the two is close to unity, indicating that cure from liver cancer is rare.

Malignant liver cancers represent primarily hepatocellular carcinomas (90%) followed by cholangiocarcinomas (10%). Other forms of malignant liver cancer, such as angiosarcoma, are extremely rare. Hepatocellular carcinomas and intrahepatic cholangiocarcinomas deserve our attention for several reasons. Firstly, their incidence is rising, and in some countries distinctly, as has been documented by a number of epidemiological studies in the last 20 years [2, 3, 4]. Rising chronic hepatitis C infections and the surge in obesity and diabetes mellitus have been proposed as explanations for the increase in hepatocellular carcinoma [5, 6, 7, 8]. A second reason is the decidedly poor prognosis of hepatocellular carcinoma and cholangiocarcinoma [9]. These tumours can grow extensively before the appearance of symptoms. When symptoms ultimately lead to diagnosis, the therapeutic options are limited and mainly palliative. Thirdly, both tumour types are often associated with underlying liver diseases [5, 3]. Eighty percent of the patients with hepatocellular carcinoma have a cirrhosis and cholangiocarcinoma is associated with cholestatic liver diseases, particularly primary sclerosing cholangitis. Reduced hepatic functions further limit treatment options.

Thus, treatment of primary liver cancer is challenging and there is a large need for progress in the short-term and long-term outcomes in these patients. In the present manuscript, epidemiological information from tumour

registries of several Swiss cantons has been combined to examine the survival pattern of patients diagnosed with primary liver cancer during the last 30 years.

Methods

This study is based on the National Core Dataset (NCD) managed by the National Institute for Cancer Epidemiology and Registration (NICER) for the purpose of national cancer monitoring in Switzerland. Sixteen of 26 Swiss cantons currently transmit cancer data annually to the NCD. Cancer cases from thirteen cantons were pooled for this report: Basel-Stadt and Basel-Landschaft (BS/BL), Fribourg (FR), Geneva (GE), Graubünden and Glarus (GR/GL), Lucerne (LU), St. Gallen, Appenzell Ausserrhoden and Appenzell Innerrhoden (SG/AR/AI), Ticino (TI), Valais (VS) and Zurich (ZH). The cantons of Neuchâtel, Jura and Vaud could not be included, because they do not provide information on survival to the NCD.

Cancer registries recorded all incident cancer cases diagnosed in their resident population and assessed cases' survival by active and/or passive follow-up. Cases were followed-up to 31 December 2010. We extracted 7,490 malignant cancer diagnoses for liver and intrahepatic bile ducts (ICD-10 C22.0-C22.9) from 1980 to 2010. For the cantons BS and BL the latest available year of diagnosis was 2008. We excluded all cases diagnosed at death (N=850; 11.3%) or with a death certificate as the only source of information (N=285; 3.8%). Patients with multiple primary tumours were included [10]. Excluded were N=96 or 1.3% of cases, because no active follow-up has been performed. A total of 6,256 cases remained for analysis, with 90% of observations uncensored (i.e. patients who have died). Recent active follow-up was lacking for

Table 1: Number of malignant hepatic cancer cases used for survival analysis in the Swiss national dataset, stratified by Swiss cantons.

Cantons	Diagnosis period	Number of cases			Person-years	% of pooled person-years
		Men	Women	Both		
ZH	1980-2010	1304	556	1860	1738	23.9
SG/AR/AI	1980-2010	533	201	734	744	10.2
GE	1980-2010	902	263	1165	1682	23.1
BS/BL	1981-2008	434	130	564	619	8.5
TI	1996-2010	602	164	766	1197	16.4
VS	1989-2010	608	119	727	869	11.9
GR/GL	1989-2010	231	93	324	324	4.4
FR	2006-2010	71	18	89	90	1.2
LU	2010	17	10	27	21	0.3
Total		4702	1554	6256	7282	100.0

N=151 (2.4%) cases. The vital status of these cases was set lost to follow-up using the date of last contact. Because we did not assume survival up to 31 December 2010 in the absence of reported death, our survival estimates will be conservative.

Completeness of case ascertainment for hepatic cancer could be assessed in the cantons GE, GR/GL, SG/AR/AI, TI and VS and was found to be slightly higher than the international standard of at least 90% within 1.5 years after the date of diagnosis for diagnosis years 2005-2010 [11]. Case finding via death certificates was substantial: between 7% and 38%, depending on cancer registry and diagnosis year. Two registries did not utilize death certificates for case finding during all diagnosis years: ZH (1980-1996) and BS/BL (1981-2001, 2008). If ZH and BS/BL were removed from the pooled dataset for the years indicated, the maximal deviation in survival proportion found in any of the analysis endpoints was 3.0% (for age-group 55-64 during period 1990-1999).

Observed survival (OS) and relative survival (RS) were derived for consecutive time intervals of increasing length after diagnosis during which the hazards were assumed

to remain constant. Time intervals were: 0-0.1, 0.1- 0.3, 0.3-0.6, 0.6-1.0, 1.0-1.5, 1.5-2.0, 2.0-2.5, 2.5-3.0, 3-4, 4-5 and 5-6 years. RS was calculated as the ratio of the observed survival of cancer cases and the expected survival of persons in the general population matching in age, sex, calendar year of death and cantonal pool [12]. Expected cancer survival was estimated using the Ederer II method applied to all-cause mortality tables for the cantons combined [13]. All-cause death probabilities, transformed from age-, sex- and calendar year-specific death rates, were interpolated and smoothed using the Elandt-Johnson formula [14]. RS ratios were estimated using the strs command (version 1.3.7) [15] written for the Stata Statistical Software [16]. Partially complete survival analysis was used for the comparison in Table 2. Period survival analysis [17] was used for the analysis of time trends in Table 3. In brief, partially complete analysis describes the survival of cases defined by dates of diagnosis, and period analysis defines cases by follow-up dates. RS estimates were age-standardized using weights specific for hepatic cancer from the International Cancer Survival Standards (ICSS) [18]. Standard weights for age groups were: 0.19 (0-54 years), 0.23 (55-64), 0.29 (65-74) and 0.29 (75-99). Ninety-five percent confidence intervals (95% CI) were estimated using Greenwood's method [19] in partially complete analysis and in period analysis by applying the delta method to a transformation of the cumulative hazard. For age-standardized RS, 95% CI were estimated as described in [18].

To test for linear time trends of RS, the annual percentage change (APC) was estimated with the Joinpoint Regression Program v4.0.4 [20].

		Observed survival %			Relative survival ¹ %								
Years since diagnosis	Age in years	Calendar period of diagnosis 1990 - 1999 ⁴											
		Men	Women	Both	Men	95% CI ³		Women	95% CI ³		Both	95% CI ³	
						LL	UL		LL	UL		LL	UL
1	00 - 54	36.8	52.6	40.4	36.9	30.0	43.9	52.7	38.8	64.9	40.5	34.3	46.7
	55 - 64	29.1	34.2	30.0	29.4	24.7	34.2	34.4	24.0	45.1	30.2	25.9	34.6
	65 - 74	26.5	26.9	26.6	27.2	23.2	31.4	27.2	19.9	35.0	27.1	23.6	30.7
	75 - 99	19.7	12.6	17.4	21.5	17.2	26.3	13.6	8.8	19.4	18.8	15.4	22.4
	00 - 99	26.8	25.7	26.5	27.7	25.3	30.2	26.4	22.3	30.7	27.3	25.2	29.4
3	00 - 54	23.7	25.8	24.2	24.0	18.0	30.6	25.9	14.7	38.6	24.4	19.0	30.2
	55 - 64	13.3	13.3	13.3	13.8	10.2	17.9	13.5	6.6	23.0	13.7	10.4	17.4
	65 - 74	9.4	7.9	9.2	10.3	7.5	13.7	8.2	3.8	14.8	9.8	7.4	12.6
	75 - 99	2.7	3.1	2.8	3.6	1.6	7.1	3.9	1.3	9.2	3.6	1.9	6.3
	00 - 99	10.8	9.3	10.5	11.9	10.0	13.9	9.9	7.1	13.5	11.3	9.7	13.0
1	stand. ²	27.1	29.3	27.3	27.9	25.5	30.4	29.8	25.4	34.2	27.9	25.8	30.1
3		11.1	11.1	11.1	11.8	10.0	13.8	11.6	8.3	15.4	11.7	10.1	13.4
		Calendar period of diagnosis: 2000 - 2009 ⁴											
1	00 - 54	50.1	55.3	51.2	50.2	44.5	55.7	55.4	44.5	65.0	51.4	46.3	56.2
	55 - 64	44.4	49.6	45.3	44.8	40.6	48.9	49.9	40.5	58.5	45.6	41.8	49.3
	65 - 74	41.1	41.2	41.1	42.0	38.4	45.5	41.6	35.0	48.1	41.8	38.7	44.9
	75 - 99	26.4	27.1	26.6	28.1	24.4	31.9	28.3	23.1	33.8	28.1	25.1	31.2
	00 - 99	39.3	38.6	39.1	40.2	38.1	42.3	39.4	35.7	43.0	39.9	38.1	41.7
3	00 - 54	27.8	28.5	28.0	28.1	22.9	33.5	28.7	19.0	39.1	28.2	23.6	33.0
	55 - 64	22.3	20.8	22.0	22.9	19.3	26.7	21.1	14.0	29.2	22.5	19.2	25.9
	65 - 74	18.4	20.5	18.9	19.6	16.7	22.7	21.3	15.9	27.2	19.8	17.3	22.5
	75 - 99	10.2	8.7	9.7	12.4	9.5	15.7	9.9	6.5	14.3	11.4	9.1	13.9
	00 - 99	18.5	16.8	18.0	19.7	18.0	21.6	17.8	14.9	20.9	19.1	17.6	20.7
1	stand. ²	39.3	41.7	39.8	40.2	38.1	42.2	42.3	38.5	46.0	40.5	38.7	42.3
3		18.7	18.7	18.7	19.9	18.1	21.7	19.4	16.2	22.7	19.6	18.0	21.2

Results

The survival experiences of more than 6,200 persons diagnosed with malignant cancer of the liver or the intrahepatic bile ducts contributed to this study (Tab. 1). The data pool contains increasing numbers of cancer registries over time. Until 1995, the cantons ZH, SG/AR/AI, GE and BS/BL contributed to the pool, whereas canton TI joined in 1996, canton FR in 2006 and canton LU in 2010. The cantons ZH and GE alone contributed almost 50% of the total cases.


Men were about three times more often affected compared to Women. The median age at diagnosis was 68 years (interquartile range IQR 60-75) for Men and 72 years (IQR 63-79) for Women. Just five percent of patients were diagnosed below age 47. The age distribution of the patients remained stable over time. The most common primary malignancy was hepatocellular carcinoma, ranging from 50% - 90% depending on cancer registry. Validity of this estimate was limited by considerable differences in the frequency of unspecified neoplasms (ranging from 1% up to 40%, depending on cancer registry).

The survival experience of Men and Women was remarkably similar, for every age-group and diagnosis period

analysed. This is shown in Tab. 2 for survival proportions at one and three years after diagnosis, and by the survival curves in Fig. 1. Estimations for survival proportions five years after diagnosis are not shown in Tab. 2 because they could not be reliably estimated in Women due to the smaller number of cases.

Men and Women shared equally in the prolongation of survival duration over calendar time. The age-standardized relative survival (RS) proportions in Men, diagnosed between 1990 and 1999, were 27.9% and 11.8% for one and three years after diagnosis, respectively, and in Women, diagnosed in the same period, RS was 29.8% and 11.6%, respectively. A decade later (2000-2009), the RS had improved considerably to 40.2% and 19.9% in Men and 42.3% and 19.4% in Women.

Figure 1: Age- and sex-specific relative survival curves for two calendar periods of diagnosis (1990-1999 and 2000-2009). 95% confidence intervals are shown for survival proportions at one and three years after diagnosis. Hepatic cancer cases were pooled from 12 Swiss cantons (ZH, SG/AR/AI, GE, BS/BL, TI, VS, GR/GL, and FR).



		Calendar period of death or censoring							APC ² [95% CI]
		1990/1992	1993/1995	1996/1998	1999/2001	2002/2004	2005/2007	2008/2010	
Years since diagnosis	Age in years	RS ¹ % [95% CI]	RS ¹ % [95% CI]	RS ¹ % [95% CI]	RS ¹ % [95% CI]	RS ¹ % [95% CI]	RS ¹ % [95% CI]	RS ¹ % [95% CI]	
Both sexes									
1	00-74	22.5 [17.8;26.6]	19.1 [15.3; 23.1]	28.1 [24.2; 32.1]	35.1 [31.0; 39.3]	39.8 [35.7; 43.7]	45.6 [41.7; 49.5]	44.2 [40.5; 47.9]	4.0 [2.0; 6.0]
	75-99	11.1 [6.9;16.6]	10.4 [6.4; 15.5]	12.5 [8.6; 17.1]	17.4 [12.8; 22.5]	18.8 [14.6; 23.4]	24.9 [20.1; 30.0]	25.8 [21.1; 30.8]	5.1 [3.5; 6.7]
5	00-74	5.0 [2.5; 8.6]	5.0 [3.1; 7.6]	7.2 [4.7; 10.4]	9.6 [7.0; 12.7]	13.2 [10.3; 16.4]	14.0 [11.3; 17.1]	15.1 [12.5; 18.0]	5.9 [3.5; 8.3]
	75-99	0.3 [0.0; 4.4]	1.0 [2.2; 4.0]	1.0 [0.2; 3.7]	4.9 [1.6; 11.6]	4.7 [2.2; 8.7]	6.2 [3.5; 10.0]	6.2 [3.6; 9.9]	9.7 [1.8; 18.2]
1	stand. ³	19.4 [16.0; 23.1]	18.5 [15.3; 22.1]	24.2 [21.1; 27.4]	30.4 [27.1; 33.7]	34.6 [31.4; 37.7]	39.9 [36.7; 43.0]	39.1 [36.1; 42.2]	3.9 [2.3; 5.6]
5		4.1 [2.3; 6.7]	4.8 [3.1; 7.1]	6.1 [4.2; 8.6]	8.2 [5.9; 11.1]	12.5 [10.1; 15.1]	11.9 [9.7; 14.4]	13.1 [10.9; 15.4]	5.6 [2.7; 8.7]

¹ RS (relative survival) analysed with period approach. CI: Confidence interval.

² Annual percentage change

³ Age standardized using ICS weights

Temporal survival trends were analysed at higher resolution using seven consecutive time periods of three year duration, starting in 1990 and ending in 2010 (Tab. 3). Men and Women were analysed together and the age groups reduced to two. The enlarged number of observations per stratum allowed estimation of five-year survival proportions. The annual percentage changes (APC) were significantly larger than zero for short term RS (one year after diagnosis) as well as for long term survival (five years after diagnosis) and ranged from 3.9% to almost 10%. Persons above 75 years of age at diagnosis seemed to have gained equally or even slightly more than younger persons (APC 9.7% vs 5.9% for RS after five years, difference not significant). The APC in age-standardized RS proportions were 3.9% [CI 2.3-5.6%] and 5.6% [CI 2.7-8.7%] for one and five year survival, respectively. The overall shape of the trend was not linear but seemed to have been steepest during the time period 1997-2003.

Discussion

Our results confirm that the prognosis of primary liver cancer is still poor. This emphasizes the role of primary prevention. It is important to treat patients with liver diseases before they develop a cirrhosis, which places them at higher carcinogenic risk. Well-tolerated, efficacious treatments against chronic hepatitis B and chronic hepatitis C infections are now available and they have been shown to decrease the rate of hepatocellular carcinoma [21, 22]. Regarding secondary prevention, relevant diagnostic procedures such as ultrasonography, computed tomography and

Table 3: Trends in relative survival of hepatic cancer cases pooled from 13 Swiss cantons (ZH, SG/AR/AI, GE, BS/BL, TI, VS, GR/GL, FR, and LU) for successive three-year calendar periods of follow-up.

magnetic resonance imaging, have been introduced during the last 20 years to detect hepatocellular carcinoma at an earlier stage. Since the Swiss trend in mortality did not decline relative to the incidence rate, it suggests that earlier diagnosis of liver cancer might have contributed to the observed prolongation of survival, measured as time from diagnosis to death or end of follow-up. Additional efforts could be made through active surveillance of patients at risk and thus offering curative treatments to a larger number of patients as has recently been shown for the Bern HCC cohort [23].

The observed improvements in survival of patients in Switzerland could have several explanations, which are mutually non-exclusive. Novel and effective treatments of hepatocellular carcinoma have been progressively introduced during the last 20 years. Selection of treatments has been facilitated with the introduction of the 'BCLC' algorithm [24] and in particular, the recognition in the late nineties, that patients with a limited tumour burden can be transplanted with a small risk of recurrence [25]. The application of the so-called «Milan criteria» not only cured patients with hepatocellular carcinoma, but also stimulated physicians to

find tumours at an earlier stage, which lead to better screening and clearer radiological definition of the diagnosis [26]. Furthermore, the use of other therapeutic options has been improved, such as transarterial chemoembolization (TACE), either as palliative intervention or as neoadjuvant treatment, the introduction of drug-eluting beads [27], and of a systemic targeted therapy against hepatocellular carcinoma [28]. The contribution of such palliative treatments on long-term survival is limited in comparison with curative approaches such as transplantation [29] or innovative therapeutic combinations [30].

The main strength of our study is the large number of primary hepatic cancer cases that could be combined from thirteen Swiss cantons. The data spans 30 calendar years, thus allowing the analysis of changes over time. There are, however, important limitations to our study. Neither the histological type of the primary tumour nor the progression stage of the disease have been taken into account. It is likely to be hepatocellular carcinoma at a progressed stage in the majority of cases, but we cannot exclude distortion of our results by other forms of hepatic carcinoma or by changes in the case mix over time.

In conclusion, primary liver cancer should attract more attention in the medical community than it does at present. The number of patients could be reduced by vaccination against hepatitis B and by treatment of chronic viral hepatitis, alcoholic liver disease and non-alcoholic steatohepatitis. In addition, increased efforts such as active surveillance of patients at risk could be made in order to diagnose hepatic cancer at an earlier stage.

References*

1. For trends of cancer incidence and mortality see NICER website at <http://nicer.org/>
2. Sherman M. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. *Semin Liver Dis*, 2010. 30(1): p. 3-16.
3. Rizvi S and Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. *Gastroenterology*, 2013. 145(6): p. 1215-29.
4. Njei B. The Changing Pattern of Epidemiology in Intrahepatic Cholangiocarcinoma. *Hepatology*, 2013.
5. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *J Hepatol*, 2012. 56(4): p. 908-43.
6. Welzel TM, et al. Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database. *Hepatology*, 2011. 54(2): p. 463-71.
7. El-Serag HB, Hampel H, and Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. *Clin Gastroenterol Hepatol*, 2006. 4(3): p. 369-80.
8. Dufour JF and Johnson P. Liver cancer: from molecular pathogenesis to new therapies: summary of the EASL single topic conference. *J Hepatol*, 2010. 52(2): p. 296-304.
9. Altekruse SE, McGlynn KA, and Reichman ME. Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States From 1975 to 2005. *J Clin Oncol*, 2009. 27(9): p. 1485-91.
10. Rosso S, et al. Multiple tumours in survival estimates. *Eur J Cancer*, 2009. 45(6): p. 1080-94.
11. Lorez M, et al. and NICER Working Group. Completeness of case ascertainment in Swiss cancer registration. 2013. (in preparation)

12. Ederer F, Axtell LM and Cutler SJ. The relative survival rate: a statistical methodology. *Natl Cancer Inst Monogr* 6 p. 101-121, 1961.
13. Ederer F and Heise H. Instructions to IBM 650 Programmers in Processing Survival Computations. Methodological note no 10, End Results Evaluation Section. 1959. Bethesda MD, National Cancer Institute.
14. Elandt-Johnson RC and Johnson NL. *Survival Models and Data Analysis*. New York: John Wiley&Sons 1980.
15. Dickman PW, Coviello E and Hills M. Estimating and modelling relative survival. *The Stata Journal* (in press).
16. StataCorp LP: *Data Analysis and Stata Statistical Software*. Release 12: 2011. College Station, TX (USA), StataCorp.
17. Brenner H and Gefeller O. An alternative approach to monitoring cancer patient survival. *Cancer*, 1996. 78(9): p. 2004-2010.
18. Corazzari I, Quinn M and Capocaccia R. Standard cancer patient population for age standardising survival ratios. *Eur J Cancer*, 2004. 40(15): p. 2307-2316.
19. Cox DR, Oakes D. *Analysis of survival data*. New York (USA), Chapman and Hall/CRC 1984.
20. Joinpoint Regression Program, Version 4.0.4 - May 2013; Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute.
21. van der Meer AJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. *Jama*, 2012. 308(24): p. 2584-93.
22. Triolo M, Corte CD, and Colombo M. Impact of HBV therapy on the incidence of hepatocellular carcinoma. *Liver Int*, 2014. 34 Suppl 1: p. 139-45.
23. Al Hasani F, Knoepfli M, Gemperli A, et al. Factors affecting screening for hepatocellular carcinoma. *Ann Hepatol* 2014, 13(2), (in press).
24. Llovet JM, Bru C, and Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. *Semin Liver Dis*, 1999. 19(3): p. 329-38.
25. Mazzaferro V, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med*, 1996. 334(11): p. 693-9.
26. Bruix J, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. *European Association for the Study of the Liver. J Hepatol*, 2001. 35(3): p. 421-30.
27. Lammer J, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. *Cardiovasc Intervent Radiol*, 2010. 33(1): p. 41-52.
28. Llovet JM, et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med*, 2008. 359(4): p. 378-90.
29. Bolondi L, et al. Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions. *Semin Liver Dis*, 2012. 32(4): p. 348-59.
30. Dufour JF, et al. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. *Oncologist*, 2010. 15(11): p. 1198-204.

* For additional information on cancer in Switzerland, please see the NICER website at <http://nicer.org/>

§Members of the NICER Working Group for these analyses included: G. Jundt (BS/BL), B. Camey (FR), C. Bouchardy (GE), H. Frick (S. Ess) (GR/GL), J. Diebold (LU), S. Ess (SG/AR/AI), A. Bordonì (TI), I. Konzelmann (VS), S. Dehler (ZH/ZG).

Correspondence:

Matthias Lorez, NICER
ml@nicer.org

Ausgezeichnete Noten für die Forschungsförderung

Rolf Marti, Stéphanie Buvelot Frei
und Kurt Bodenmüller, Krebsliga Schweiz

Die Stiftung Krebsforschung Schweiz und die Krebsliga Schweiz leisten hervorragende Arbeit bei der Förderung der Krebsforschung in der Schweiz. Sie unterstützen Forschungsprojekte von ausgezeichneter Qualität, aus denen viele bedeutende Publikationen hervorgehen – mit Topwerten im internationalen Vergleich. Dies sind die Ergebnisse einer unabhängigen, extern durchgeführten Evaluation.

D'excellentes notes pour la promotion de la recherche

La fondation Recherche suisse contre le cancer et la Ligue suisse contre le cancer réalisent un travail remarquable en matière de promotion de la recherche oncologique en Suisse. Elles soutiennent des projets d'excellente qualité qui génèrent un grand nombre de publications importantes et qui sont extrêmement bien notées en comparaison internationale. Tels sont les résultats d'une évaluation externe indépendante.

Pour en savoir plus: www.liguecancer.ch/pr-evaluation

Dank ihren zahlreichen Spenderinnen und Spendern haben die Stiftung Krebsforschung Schweiz (KFS) und die Krebsliga Schweiz (KLS) im Jahr 2013 die onkologische Forschung mit über 17 Millionen Franken unterstützt. Gefördert wurden insgesamt 63 Forschungsprojekte aus dem gesamten Spektrum der Krebsforschung, zehn Stipendiaten, sieben Schweizer Forschungsorganisationen sowie 42 wissenschaftliche Kongresse, Workshops und weitere Projekte und Organisationen. 80% der Mittel stammten von der KFS und 20% steuerte die KLS bei. Zusätzlich dazu fördern diverse kantonale und regionale Krebsligen die Krebsforschung mit über drei Millionen Franken pro Jahr.

Umfassende unabhängige Evaluation

Hauptkriterium für den Entscheid, welche Projekte finanziert werden, ist die Qualität der eingereichten Arbeiten. Ein wichtiger Fokus liegt in der Unterstützung der

patientennahen Forschung. Die Mitglieder der Wissenschaftlichen Kommission (WiKo) evaluieren zusammen mit weiteren internationalen Fachpersonen sämtliche Gesuche nach klar definierten wissenschaftlichen Kriterien. Zuständig für den Entscheid, welche Gesuche finanzielle Unterstützung erhalten, sind der Stiftungsrat der KFS und der Vorstand der KLS. Der Bereich Forschungsförderung der KLS («Scientific Office») fungiert als Kompetenzzentrum und operationelle Drehscheibe der Forschungsförderung beider Organisationen.

Im Auftrag der Vorstände von KFS und KLS hat die Firma evaluateSCIENCE Qualität und Effizienz der Forschungsförderung, die beteiligten Organe sowie Steuerung, Prozesse und Strukturen überprüft. Die Auswertung basiert auf dem Zeitraum 1998–2012 sowie internationalen Standards (Methode: «Informed Peer Review» gemäss «Zürich Model», eine an der Universität Zürich entwickelte Evaluationsmethode). Ausgangspunkt bildete ein umfangreicher, vom Bereich Forschungsförderung erarbeiteter Selbstbericht. Die Evaluation von evaluateSCIENCE beinhaltete drei Schwerpunkte: eine bibliometrische Analyse der wissenschaftlichen Publikationen, eine Online-Umfrage bei den Forschenden und die Beurteilung durch eine unabhängige internationale Expertengruppe.

Bibliometrie: exzellenter «Output»

Wie gut die Qualität einer Forschungsarbeit ist bzw. welche Bedeutung diese innerhalb eines bestimmten Forschungsgebiets hat, wird hauptsächlich durch zwei Faktoren bestimmt: in welcher Fachzeitschrift die Arbeit publiziert wurde («impact factor») und wie oft die Arbeit in weiteren Publikationen zitiert wurde («citations»). Je renommierter die Fachzeitschrift ist und je öfter die Publikation zitiert wird, desto bedeutender ist sie. Insgesamt wurden über 400 von KFS bzw. KLS im Zeitraum 1998–2006 finanzierte Forschungsprojekte quantitativ und qualitativ ausgewertet.

Die wichtigsten Ergebnisse:

- KFS und KLS förderten Forschungsarbeiten von ausgezeichneter Qualität. Insbesondere Projekte in den Bereichen Grundlagenforschung, epidemiologische und labororientierte klinische Forschung resultierten in Publikationen von grosser bis sehr grosser wissenschaftlicher Bedeutung im jeweiligen Forschungsgebiet. Auch die Fördereffizienz, d.h. der finanzielle Aufwand pro Publikation, war für diese drei Forschungsbereiche am höchsten.
- Kleiner fiel im Vergleich der wissenschaftliche «Output» sowie die Fördereffizienz bei patientenorientierten Forschungsprojekten aus. Zurückzuführen ist dies u.a. darauf, dass klinische Studien viel aufwendiger und teurer sind und es länger dauert, bis publizierbare Resultate vorliegen.